Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

In March of 2018, the National Kidney Foundation, in collaboration with the US Food and Drug Administration and the European Medicines Agency, sponsored a workshop in which surrogate endpoints other than currently established event‐time endpoints for clinical trials in chronic kidney disease (CKD) w...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Vonesh, E, Tighiouart, H, Ying, J, Heerspink, HL, Lewis, J, Staplin, N, Inker, L, Greene, T
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Wiley 2019

Παρόμοια τεκμήρια

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
ανά: Inker, LA, κ.ά.
Έκδοση: (2023)

Acute treatment effects on GFR in randomized clinical trials of kidney disease progression
ανά: Neuen, B, κ.ά.
Έκδοση: (2021)

Allograft function as endpoint for clinical trials in kidney transplantation
ανά: Hilbrands, L, κ.ά.
Έκδοση: (2022)

Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
ανά: Tong, A, κ.ά.
Έκδοση: (2022)

Renal end points in clinical trials of kidney disease
ανά: Weldegiorgis, M, κ.ά.
Έκδοση: (2015)

Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes
ανά: Mackay, M, κ.ά.
Έκδοση: (2019)

Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation
ανά: Roufosse, C, κ.ά.
Έκδοση: (2022)

Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
ανά: Seron, D, κ.ά.
Έκδοση: (2022)

2017 cardiovascular and stroke endpoint definitions for clinical trials
ανά: Hicks, KA, κ.ά.
Έκδοση: (2018)

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
ανά: Hicks, KA, κ.ά.
Έκδοση: (2018)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
ανά: Zhu, D, κ.ά.
Έκδοση: (2025)

Increasing the use of mobile technology-derived endpoints in clinical trials.
ανά: Herrington, W, κ.ά.
Έκδοση: (2018)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
ανά: Mayne, K, κ.ά.
Έκδοση: (2024)

Development of standard clinical endpoints for use in dengue interventional trials
ανά: Tomashek, Kay M., κ.ά.
Έκδοση: (2018)

Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
ανά: Jeeyapant, A, κ.ά.
Έκδοση: (2017)

Lipids in chronic kidney disease.
ανά: Lewis, D, κ.ά.
Έκδοση: (2010)

Development of standard clinical endpoints for use in dengue interventional trials
ανά: Tomashek, K, κ.ά.
Έκδοση: (2018)

The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
ανά: Thorlund, K, κ.ά.
Έκδοση: (2023)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
ανά: Staplin, N, κ.ά.
Έκδοση: (2023)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
ανά: D'Haens, G, κ.ά.
Έκδοση: (2009)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
ανά: Staplin, N, κ.ά.
Έκδοση: (2023)

Evaluating glomerular filtration rate slope as a surrogate endpoint for ESKD in clinical trials: an individual participant meta-analysis of observational data
ανά: Grams, M, κ.ά.
Έκδοση: (2019)

Rock endpoints and barriers estimation of slope failure in Pinousuk Gravel slopes using Rocfall simulation
ανά: H F W S Erfen, κ.ά.
Έκδοση: (2022)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
ανά: Preiss, D, κ.ά.
Έκδοση: (2022)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
ανά: Kitley, J, κ.ά.
Έκδοση: (2014)

Chronic kidney disease
ανά: de Lusignan, S
Έκδοση: (2006)

Empagliflozin in patients with chronic kidney disease
ανά: Herrington, WG, κ.ά.
Έκδοση: (2022)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
ανά: Zhu, P, κ.ά.
Έκδοση: (2020)

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate
ανά: Grams, M, κ.ά.
Έκδοση: (2018)

Kidney disease trials for the 21st century: innovations in design and conduct
ανά: Herrington, W, κ.ά.
Έκδοση: (2019)

Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation
ανά: Naesens, M, κ.ά.
Έκδοση: (2022)

Is “chronic kidney disease” a disease?
ανά: Smart, B, κ.ά.
Έκδοση: (2018)

Genetic loci influencing kidney function and chronic kidney disease.
ανά: Chambers, J, κ.ά.
Έκδοση: (2010)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
ανά: Gottlieb, K, κ.ά.
Έκδοση: (2015)

What drives quality improvement in chronic kidney disease (CKD) in primary care: process evaluation of the Quality Improvement in Chronic Kidney Disease (QICKD) trial
ανά: Nihat, A, κ.ά.
Έκδοση: (2016)

Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data
ανά: Dmitrieva, O, κ.ά.
Έκδοση: (2013)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
ανά: Staplin, N, κ.ά.
Έκδοση: (2022)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
ανά: Haynes, R, κ.ά.
Έκδοση: (2018)

New loci associated with kidney function and chronic kidney disease.
ανά: Köttgen, A, κ.ά.
Έκδοση: (2010)